India CROs Say DCGI Trial-Approval Switch To NDAC Too Costly
This article was originally published in PharmAsia News
India's clinical-research organizations say they are taking a direct hit as a result of the decision by the Drug Controller General of India to cede its authority over clinical trials to the New-Drug Advisory Committee.
You may also be interested in...
US FDA looks to post-marketing studies to address elements of the NDA that were not central to its initial swift approval as the first COVID-19 therapy, including pediatric use and the interaction of hepatotoxicity and dose duration.
But advisory committee members caution against including pediatric population in COVID-19 vaccine trials, and one member expresses concern that Pfizer is testing those as young as 12 years of age. Agency is in discussions with product sponsors about enrollment of adolescents.
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.